ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hormone Refractory Breast Cancer Market Insights, Forecast to 2030
Published Date: December 2024
|
Report Code: QYRE-Auto-22D2735
Home | Market Reports | Health| Health Conditions| Cancer
Global Hormone Refractory Breast Cancer Market Insights Forecast to 2028
BUY CHAPTERS

Global Hormone Refractory Breast Cancer Market Insights, Forecast to 2030

Code: QYRE-Auto-22D2735
Report
December 2024
Pages:94
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
AmpliMed Corporation
Roche
Bluefish Pharmaceuticals AB
NeoCorp
Sanofi Genzyme
Neopharm
Boehringer Ingelheim GmbH

Hormone Refractory Breast Cancer Market

An increasing number of hormone therapies have made refractory breast cancer resistant to treatment, increased incidence of breast cancer, aging population, increased demand for advanced therapies, increased incidence of hormone-refractory breast cancer and the existence of a large number of anti-cancer pipeline drugs, all of which drive the growth of hormone-refractory breast cancer market.
Market Analysis and Insights: Global Hormone Refractory Breast Cancer Market
The global Hormone Refractory Breast Cancer market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Hormone Refractory Breast Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Hormone Refractory Breast Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Hormone Refractory Breast Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Hormone Refractory Breast Cancer include AstraZeneca, AmpliMed Corporation, Roche, Bluefish Pharmaceuticals AB, NeoCorp, Sanofi Genzyme, Neopharm and Boehringer Ingelheim GmbH, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Hormone Refractory Breast Cancer is widely used in various fields, such as Scientific Research and Production, Biological Science and Technology, Medical Technology and Medical Apparatus and Instruments, etc. Scientific Research and Production provides greatest supports to the Hormone Refractory Breast Cancer industry development. In 2023, global % revenue of Hormone Refractory Breast Cancer went into Scientific Research and Production filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Hormone Refractory Breast Cancer market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Hormone Refractory Breast Cancer, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Hormone Refractory Breast Cancer, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Hormone Refractory Breast Cancer revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Hormone Refractory Breast Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Hormone Refractory Breast Cancer revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation

Scope of Hormone Refractory Breast Cancer Market Report

Report Metric Details
Report Name Hormone Refractory Breast Cancer Market
Segment by Type
Segment by Application
  • Scientific Research and Production
  • Biological Science and Technology
  • Medical Technology
  • Medical Apparatus and Instruments
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company AstraZeneca, AmpliMed Corporation, Roche, Bluefish Pharmaceuticals AB, NeoCorp, Sanofi Genzyme, Neopharm, Boehringer Ingelheim GmbH
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of Hormone Refractory Breast Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Hormone Refractory Breast Cancer companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 8: China by Type, and by Application, revenue for each segment.
  • Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hormone Refractory Breast Cancer revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

Who are the main players in the Hormone Refractory Breast Cancer Market report?

Ans: The main players in the Hormone Refractory Breast Cancer Market are AstraZeneca, AmpliMed Corporation, Roche, Bluefish Pharmaceuticals AB, NeoCorp, Sanofi Genzyme, Neopharm, Boehringer Ingelheim GmbH

What are the Application segmentation covered in the Hormone Refractory Breast Cancer Market report?

Ans: The Applications covered in the Hormone Refractory Breast Cancer Market report are Scientific Research and Production, Biological Science and Technology, Medical Technology, Medical Apparatus and Instruments

What are the Type segmentation covered in the Hormone Refractory Breast Cancer Market report?

Ans: The Types covered in the Hormone Refractory Breast Cancer Market report are Tumor Markers Therapy, Gene Expression Therapy, Gene Mutation Therapy

Recommended Reports

Breast Cancer Therapeutics

Cancer Therapeutics & Support

Other Hormonal Oncology

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Tumor Markers Therapy
1.2.3 Gene Expression Therapy
1.2.4 Gene Mutation Therapy
1.3 Market by Application
1.3.1 Global Hormone Refractory Breast Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Scientific Research and Production
1.3.3 Biological Science and Technology
1.3.4 Medical Technology
1.3.5 Medical Apparatus and Instruments
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hormone Refractory Breast Cancer Market Perspective (2019-2030)
2.2 Global Hormone Refractory Breast Cancer Growth Trends by Region
2.2.1 Hormone Refractory Breast Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hormone Refractory Breast Cancer Historic Market Size by Region (2019-2024)
2.2.3 Hormone Refractory Breast Cancer Forecasted Market Size by Region (2025-2030)
2.3 Hormone Refractory Breast Cancer Market Dynamics
2.3.1 Hormone Refractory Breast Cancer Industry Trends
2.3.2 Hormone Refractory Breast Cancer Market Drivers
2.3.3 Hormone Refractory Breast Cancer Market Challenges
2.3.4 Hormone Refractory Breast Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Hormone Refractory Breast Cancer by Players
3.1.1 Global Hormone Refractory Breast Cancer Revenue by Players (2019-2024)
3.1.2 Global Hormone Refractory Breast Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Hormone Refractory Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Hormone Refractory Breast Cancer, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Hormone Refractory Breast Cancer Market Concentration Ratio
3.4.1 Global Hormone Refractory Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hormone Refractory Breast Cancer Revenue in 2023
3.5 Global Key Players of Hormone Refractory Breast Cancer Head office and Area Served
3.6 Global Key Players of Hormone Refractory Breast Cancer, Product and Application
3.7 Global Key Players of Hormone Refractory Breast Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Hormone Refractory Breast Cancer Breakdown Data by Type
4.1 Global Hormone Refractory Breast Cancer Historic Market Size by Type (2019-2024)
4.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Type (2025-2030)
5 Hormone Refractory Breast Cancer Breakdown Data by Application
5.1 Global Hormone Refractory Breast Cancer Historic Market Size by Application (2019-2024)
5.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hormone Refractory Breast Cancer Market Size (2019-2030)
6.2 North America Hormone Refractory Breast Cancer Market Size by Type
6.2.1 North America Hormone Refractory Breast Cancer Market Size by Type (2019-2024)
6.2.2 North America Hormone Refractory Breast Cancer Market Size by Type (2025-2030)
6.2.3 North America Hormone Refractory Breast Cancer Market Share by Type (2019-2030)
6.3 North America Hormone Refractory Breast Cancer Market Size by Application
6.3.1 North America Hormone Refractory Breast Cancer Market Size by Application (2019-2024)
6.3.2 North America Hormone Refractory Breast Cancer Market Size by Application (2025-2030)
6.3.3 North America Hormone Refractory Breast Cancer Market Share by Application (2019-2030)
6.4 North America Hormone Refractory Breast Cancer Market Size by Country
6.4.1 North America Hormone Refractory Breast Cancer Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Hormone Refractory Breast Cancer Market Size by Country (2019-2024)
6.4.3 North America Hormone Refractory Breast Cancer Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Hormone Refractory Breast Cancer Market Size (2019-2030)
7.2 Europe Hormone Refractory Breast Cancer Market Size by Type
7.2.1 Europe Hormone Refractory Breast Cancer Market Size by Type (2019-2024)
7.2.2 Europe Hormone Refractory Breast Cancer Market Size by Type (2025-2030)
7.2.3 Europe Hormone Refractory Breast Cancer Market Share by Type (2019-2030)
7.3 Europe Hormone Refractory Breast Cancer Market Size by Application
7.3.1 Europe Hormone Refractory Breast Cancer Market Size by Application (2019-2024)
7.3.2 Europe Hormone Refractory Breast Cancer Market Size by Application (2025-2030)
7.3.3 Europe Hormone Refractory Breast Cancer Market Share by Application (2019-2030)
7.4 Europe Hormone Refractory Breast Cancer Market Size by Country
7.4.1 Europe Hormone Refractory Breast Cancer Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Hormone Refractory Breast Cancer Market Size by Country (2019-2024)
7.4.3 Europe Hormone Refractory Breast Cancer Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Hormone Refractory Breast Cancer Market Size (2019-2030)
8.2 China Hormone Refractory Breast Cancer Market Size by Type
8.2.1 China Hormone Refractory Breast Cancer Market Size by Type (2019-2024)
8.2.2 China Hormone Refractory Breast Cancer Market Size by Type (2025-2030)
8.2.3 China Hormone Refractory Breast Cancer Market Share by Type (2019-2030)
8.3 China Hormone Refractory Breast Cancer Market Size by Application
8.3.1 China Hormone Refractory Breast Cancer Market Size by Application (2019-2024)
8.3.2 China Hormone Refractory Breast Cancer Market Size by Application (2025-2030)
8.3.3 China Hormone Refractory Breast Cancer Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Hormone Refractory Breast Cancer Market Size (2019-2030)
9.2 Asia Hormone Refractory Breast Cancer Market Size by Type
9.2.1 Asia Hormone Refractory Breast Cancer Market Size by Type (2019-2024)
9.2.2 Asia Hormone Refractory Breast Cancer Market Size by Type (2025-2030)
9.2.3 Asia Hormone Refractory Breast Cancer Market Share by Type (2019-2030)
9.3 Asia Hormone Refractory Breast Cancer Market Size by Application
9.3.1 Asia Hormone Refractory Breast Cancer Market Size by Application (2019-2024)
9.3.2 Asia Hormone Refractory Breast Cancer Market Size by Application (2025-2030)
9.3.3 Asia Hormone Refractory Breast Cancer Market Share by Application (2019-2030)
9.4 Asia Hormone Refractory Breast Cancer Market Size by Region
9.4.1 Asia Hormone Refractory Breast Cancer Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Hormone Refractory Breast Cancer Market Size by Region (2019-2024)
9.4.3 Asia Hormone Refractory Breast Cancer Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Type
10.2.1 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Application
10.3.1 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Country
10.4.1 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Hormone Refractory Breast Cancer Introduction
11.1.4 AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.1.5 AstraZeneca Recent Developments
11.2 AmpliMed Corporation
11.2.1 AmpliMed Corporation Company Details
11.2.2 AmpliMed Corporation Business Overview
11.2.3 AmpliMed Corporation Hormone Refractory Breast Cancer Introduction
11.2.4 AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.2.5 AmpliMed Corporation Recent Developments
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Hormone Refractory Breast Cancer Introduction
11.3.4 Roche Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.3.5 Roche Recent Developments
11.4 Bluefish Pharmaceuticals AB
11.4.1 Bluefish Pharmaceuticals AB Company Details
11.4.2 Bluefish Pharmaceuticals AB Business Overview
11.4.3 Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Introduction
11.4.4 Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.4.5 Bluefish Pharmaceuticals AB Recent Developments
11.5 NeoCorp
11.5.1 NeoCorp Company Details
11.5.2 NeoCorp Business Overview
11.5.3 NeoCorp Hormone Refractory Breast Cancer Introduction
11.5.4 NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.5.5 NeoCorp Recent Developments
11.6 Sanofi Genzyme
11.6.1 Sanofi Genzyme Company Details
11.6.2 Sanofi Genzyme Business Overview
11.6.3 Sanofi Genzyme Hormone Refractory Breast Cancer Introduction
11.6.4 Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.6.5 Sanofi Genzyme Recent Developments
11.7 Neopharm
11.7.1 Neopharm Company Details
11.7.2 Neopharm Business Overview
11.7.3 Neopharm Hormone Refractory Breast Cancer Introduction
11.7.4 Neopharm Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.7.5 Neopharm Recent Developments
11.8 Boehringer Ingelheim GmbH
11.8.1 Boehringer Ingelheim GmbH Company Details
11.8.2 Boehringer Ingelheim GmbH Business Overview
11.8.3 Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Introduction
11.8.4 Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.8.5 Boehringer Ingelheim GmbH Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Astrazeneca plc
AmpliMed Corporation
Roche
Bluefish Pharmaceuticals AB
NeoCorp
Sanofi Genzyme
Neopharm
Boehringer Ingelheim GmbH
List of Tables
    Table 1. Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Tumor Markers Therapy
    Table 3. Key Players of Gene Expression Therapy
    Table 4. Key Players of Gene Mutation Therapy
    Table 5. Global Hormone Refractory Breast Cancer Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 6. Global Hormone Refractory Breast Cancer Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Hormone Refractory Breast Cancer Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Hormone Refractory Breast Cancer Market Share by Region (2019-2024)
    Table 9. Global Hormone Refractory Breast Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Hormone Refractory Breast Cancer Market Share by Region (2025-2030)
    Table 11. Hormone Refractory Breast Cancer Market Trends
    Table 12. Hormone Refractory Breast Cancer Market Drivers
    Table 13. Hormone Refractory Breast Cancer Market Challenges
    Table 14. Hormone Refractory Breast Cancer Market Restraints
    Table 15. Global Hormone Refractory Breast Cancer Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Hormone Refractory Breast Cancer Revenue Share by Players (2019-2024)
    Table 17. Global Top Hormone Refractory Breast Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Breast Cancer as of 2023)
    Table 18. Global Hormone Refractory Breast Cancer Industry Ranking 2022 VS 2023 VS 2024
    Table 19. Global 5 Largest Players Market Share by Hormone Refractory Breast Cancer Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Global Key Players of Hormone Refractory Breast Cancer, Headquarters and Area Served
    Table 21. Global Key Players of Hormone Refractory Breast Cancer, Product and Application
    Table 22. Global Key Players of Hormone Refractory Breast Cancer, Product and Application
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Hormone Refractory Breast Cancer Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Hormone Refractory Breast Cancer Revenue Market Share by Type (2019-2024)
    Table 26. Global Hormone Refractory Breast Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Hormone Refractory Breast Cancer Revenue Market Share by Type (2025-2030)
    Table 28. Global Hormone Refractory Breast Cancer Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Hormone Refractory Breast Cancer Revenue Share by Application (2019-2024)
    Table 30. Global Hormone Refractory Breast Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Hormone Refractory Breast Cancer Revenue Share by Application (2025-2030)
    Table 32. North America Hormone Refractory Breast Cancer Market Size by Type (2019-2024) & (US$ Million)
    Table 33. North America Hormone Refractory Breast Cancer Market Size by Type (2025-2030) & (US$ Million)
    Table 34. North America Hormone Refractory Breast Cancer Market Size by Application (2019-2024) & (US$ Million)
    Table 35. North America Hormone Refractory Breast Cancer Market Size by Application (2025-2030) & (US$ Million)
    Table 36. North America Hormone Refractory Breast Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. North America Hormone Refractory Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
    Table 38. North America Hormone Refractory Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Europe Hormone Refractory Breast Cancer Market Size by Type (2019-2024) & (US$ Million)
    Table 40. Europe Hormone Refractory Breast Cancer Market Size by Type (2025-2030) & (US$ Million)
    Table 41. Europe Hormone Refractory Breast Cancer Market Size by Application (2019-2024) & (US$ Million)
    Table 42. Europe Hormone Refractory Breast Cancer Market Size by Application (2025-2030) & (US$ Million)
    Table 43. Europe Hormone Refractory Breast Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Europe Hormone Refractory Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Europe Hormone Refractory Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
    Table 46. China Hormone Refractory Breast Cancer Market Size by Type (2019-2024) & (US$ Million)
    Table 47. China Hormone Refractory Breast Cancer Market Size by Type (2025-2030) & (US$ Million)
    Table 48. China Hormone Refractory Breast Cancer Market Size by Application (2019-2024) & (US$ Million)
    Table 49. China Hormone Refractory Breast Cancer Market Size by Application (2025-2030) & (US$ Million)
    Table 50. Asia Hormone Refractory Breast Cancer Market Size by Type (2019-2024) & (US$ Million)
    Table 51. Asia Hormone Refractory Breast Cancer Market Size by Type (2025-2030) & (US$ Million)
    Table 52. Asia Hormone Refractory Breast Cancer Market Size by Application (2019-2024) & (US$ Million)
    Table 53. Asia Hormone Refractory Breast Cancer Market Size by Application (2025-2030) & (US$ Million)
    Table 54. Asia Hormone Refractory Breast Cancer Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 55. Asia Hormone Refractory Breast Cancer Market Size by Region (2019-2024) & (US$ Million)
    Table 56. Asia Hormone Refractory Breast Cancer Market Size by Region (2025-2030) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Type (2019-2024) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Type (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Application (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Application (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 62. Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
    Table 64. AstraZeneca Company Details
    Table 65. AstraZeneca Business Overview
    Table 66. AstraZeneca Hormone Refractory Breast Cancer Product
    Table 67. AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2019-2024) & (US$ Million)
    Table 68. AstraZeneca Recent Developments
    Table 69. AmpliMed Corporation Company Details
    Table 70. AmpliMed Corporation Business Overview
    Table 71. AmpliMed Corporation Hormone Refractory Breast Cancer Product
    Table 72. AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2019-2024) & (US$ Million)
    Table 73. AmpliMed Corporation Recent Developments
    Table 74. Roche Company Details
    Table 75. Roche Business Overview
    Table 76. Roche Hormone Refractory Breast Cancer Product
    Table 77. Roche Revenue in Hormone Refractory Breast Cancer Business (2019-2024) & (US$ Million)
    Table 78. Roche Recent Developments
    Table 79. Bluefish Pharmaceuticals AB Company Details
    Table 80. Bluefish Pharmaceuticals AB Business Overview
    Table 81. Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Product
    Table 82. Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2019-2024) & (US$ Million)
    Table 83. Bluefish Pharmaceuticals AB Recent Developments
    Table 84. NeoCorp Company Details
    Table 85. NeoCorp Business Overview
    Table 86. NeoCorp Hormone Refractory Breast Cancer Product
    Table 87. NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2019-2024) & (US$ Million)
    Table 88. NeoCorp Recent Developments
    Table 89. Sanofi Genzyme Company Details
    Table 90. Sanofi Genzyme Business Overview
    Table 91. Sanofi Genzyme Hormone Refractory Breast Cancer Product
    Table 92. Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2019-2024) & (US$ Million)
    Table 93. Sanofi Genzyme Recent Developments
    Table 94. Neopharm Company Details
    Table 95. Neopharm Business Overview
    Table 96. Neopharm Hormone Refractory Breast Cancer Product
    Table 97. Neopharm Revenue in Hormone Refractory Breast Cancer Business (2019-2024) & (US$ Million)
    Table 98. Neopharm Recent Developments
    Table 99. Boehringer Ingelheim GmbH Company Details
    Table 100. Boehringer Ingelheim GmbH Business Overview
    Table 101. Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Product
    Table 102. Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2019-2024) & (US$ Million)
    Table 103. Boehringer Ingelheim GmbH Recent Developments
    Table 104. Research Programs/Design for This Report
    Table 105. Key Data Information from Secondary Sources
    Table 106. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Hormone Refractory Breast Cancer Market Share by Type: 2023 VS 2030
    Figure 3. Tumor Markers Therapy Features
    Figure 4. Gene Expression Therapy Features
    Figure 5. Gene Mutation Therapy Features
    Figure 6. Global Hormone Refractory Breast Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Hormone Refractory Breast Cancer Market Share by Application: 2023 VS 2030
    Figure 8. Scientific Research and Production Case Studies
    Figure 9. Biological Science and Technology Case Studies
    Figure 10. Medical Technology Case Studies
    Figure 11. Medical Apparatus and Instruments Case Studies
    Figure 12. Hormone Refractory Breast Cancer Report Years Considered
    Figure 13. Global Hormone Refractory Breast Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 14. Global Hormone Refractory Breast Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 15. Global Hormone Refractory Breast Cancer Market Share by Region: 2023 VS 2030
    Figure 16. Global Hormone Refractory Breast Cancer Market Share by Players in 2023
    Figure 17. Global Top Hormone Refractory Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Breast Cancer as of 2023)
    Figure 18. The Top 10 and 5 Players Market Share by Hormone Refractory Breast Cancer Revenue in 2023
    Figure 19. North America Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 20. North America Hormone Refractory Breast Cancer Market Share by Type (2019-2030)
    Figure 21. North America Hormone Refractory Breast Cancer Market Share by Application (2019-2030)
    Figure 22. North America Hormone Refractory Breast Cancer Market Share by Country (2019-2030)
    Figure 23. United States Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Canada Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Europe Hormone Refractory Breast Cancer Market Size YoY (2019-2030) & (US$ Million)
    Figure 26. Europe Hormone Refractory Breast Cancer Market Share by Type (2019-2030)
    Figure 27. Europe Hormone Refractory Breast Cancer Market Share by Application (2019-2030)
    Figure 28. Europe Hormone Refractory Breast Cancer Market Share by Country (2019-2030)
    Figure 29. Germany Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. France Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. U.K. Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Italy Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Russia Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Nordic Countries Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. China Hormone Refractory Breast Cancer Market Size YoY (2019-2030) & (US$ Million)
    Figure 36. China Hormone Refractory Breast Cancer Market Share by Type (2019-2030)
    Figure 37. China Hormone Refractory Breast Cancer Market Share by Application (2019-2030)
    Figure 38. Asia Hormone Refractory Breast Cancer Market Size YoY (2019-2030) & (US$ Million)
    Figure 39. Asia Hormone Refractory Breast Cancer Market Share by Type (2019-2030)
    Figure 40. Asia Hormone Refractory Breast Cancer Market Share by Application (2019-2030)
    Figure 41. Asia Hormone Refractory Breast Cancer Market Share by Region (2019-2030)
    Figure 42. Japan Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. South Korea Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. China Taiwan Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Southeast Asia Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. India Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Australia Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Size YoY (2019-2030) & (US$ Million)
    Figure 49. Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Share by Type (2019-2030)
    Figure 50. Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Share by Application (2019-2030)
    Figure 51. Middle East, Africa, and Latin America Hormone Refractory Breast Cancer Market Share by Country (2019-2030)
    Figure 52. Brazil Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Mexico Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Turkey Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Saudi Arabia Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Israel Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. GCC Countries Hormone Refractory Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. AstraZeneca Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2019-2024)
    Figure 59. AmpliMed Corporation Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2019-2024)
    Figure 60. Roche Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2019-2024)
    Figure 61. Bluefish Pharmaceuticals AB Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2019-2024)
    Figure 62. NeoCorp Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2019-2024)
    Figure 63. Sanofi Genzyme Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2019-2024)
    Figure 64. Neopharm Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2019-2024)
    Figure 65. Boehringer Ingelheim GmbH Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2019-2024)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Breast Cancer Drugs Market Insights Forecast to 2030
Global Breast Cancer Hormone Therapy Market Insights Forecast to 2030
Global Checkpoint Inhibitor Refractory Cancer Market Research Report 2025
Global Metastatic Colorectal Cancer Drug Market Insights Forecast to 2030
Global Endocrine Therapy Drugs for Breast Cancer Market Research Report 2024
Breast Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hormone Antineoplastic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drug Delivery in Cancer Market Insights Forecast to 2030
Drugs for HR HER2 Advanced Breast Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Menopause Hormonal Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Breast Cancer Generic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Immuno Oncology Treatment Market Insights Forecast to 2030
Menopause Hormonal Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hormone Disorder Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drugs for Breast Cancer Market Research Report 2024
Global Cancer Hormone Therapy Drugs Market Insights Forecast to 2030
HER 2 Negative Breast Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Postmenopausal Breast Cancer Treatment Drugs Market Research Report 2024
Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Medication Treatment of Metastatic Bone Disease Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions